

JFW

4943-103 US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450 on August 18, 2004.


Diane Dunn McKay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bourassa, et al.

Customer No.: 26817

Serial No.: 10/796,936

Group Art Unit: 1614

Filed: March 10, 2004

Examiner: TBD

Confirmation No.: 3284

Title: Method and Compound To Reduce The Incidence Of Diabetes In A Subject With Chronic Heart Failure

Supplemental Information Disclosure Statement
--

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant hereby brings to the attention of the United States Patent and Trademark Office the following documents of which Applicant has been made aware. The documents are listed on the attached PTO Form 1449. Copies of the documents are enclosed.

Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication as this requirement is waived, copies of the U.S. patent and U.S. patent application publications are not submitted.

Applicant submits that this Supplemental Information Disclosure Statement is submitted within six months of the filing date.

It is requested that the references be considered by the Examiner and be made of record as part of the available prior art under 37 C.F.R. § 1.104. It is believed that no fee is required. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 13-2165.

Respectfully submitted,




Diane Dunn McKay

Reg. No. 34,586

Attorney for Applicant

Date: 8/18/04

MATHEWS, COLLINS, SHEPHERD & McKAY
100 Thanet Circle, Suite 306
Princeton, NJ 08540
(609) 924-8555 - Telephone
(609) 924-3036 - Facsimile

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Docket Number (Optional) 4943-103 US		Application Number 10/796,936	
				Applicant(s) Bourassa, et al.		Group Art Unit 1614	
				Filing Date March 10, 2004			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
		WO 01/15673 A2	03/08/2001	WIPO			
		WO 03/032963 A2	04/24/2003	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Emmanuelle Vermes, et al.; Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure; 2003; Circulation; 107 (9): 1291					
		L. Ryden, et al.; Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus; European Heart Journal; 2000; Vol. 21; 1967-1978					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							